title: [Role of pFox inhibitors in the treatment of patients with acute myocardial ischemia].
abstract: OBJECTIVE
  To evaluate the anti-ischemic and anti-anginal efficacy of meldonium (Idrinol) in its short-term use as part of combination therapy in patients with chronic heart failure in the early post-infarction period.
  
  
  METHODS
  The investigation enrolled 60 patients (men and women) aged 45 to 75 years at weeks 3-4 after postmyocardial infarction with symptoms of Functional Class II-III heart failure. All the patients underwent physical examination, 24-hour ECG monitoring, heart rate variability (HRV) study, and quality of life assessment using the Seattle questionnaire. After randomization of the patients into 2 groups, Group 1 (a study group) (n = 30) was given intravenous Idrinol 1000 mg/day in addition to the basic therapy of coronary heart disease. The study and control (Group 2; n = 30) groups were matched for age, gender, disease severity, and basic therapy pattern.
  
  
  RESULTS
  Following 10-14 days of treatment, both groups showed clinical improvement and the autonomically normalizing effect of meldonium (Idrinol), which were more pronounced in Group 1 patients.
  
  
  CONCLUSIONS
  Meldonium (Idrinol) was effective when parenterally administered in a dose of 1000 mg/day for 10-14 days as part of combination therapy in the early post-infarction period, which showed up as clinical improvement, a significant reduction in the frequency of angina attacks and in the need to use nitroglycerin, a decrease in the number of arrhythmia episodes, and its normalizing effect of HRV.
authors.forename: M E
authors.initials: ME
authors.lastname: Statsenko
authors.forename: S V
authors.initials: SV
authors.lastname: Turkina
authors.forename: N N
authors.initials: NN
authors.lastname: Shilina
mesh_terms: D000284:Administration, Oral; D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography / Q000187:drug effects; D017079:Exercise Tolerance / Q000187:drug effects*; D005260:Female; D051858:Forkhead Transcription Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D051858:Forkhead Transcription Factors; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate